ReviewNeurotoxicity research2004
Neuroprotective strategies for HIV-1 associated dementia.
Review in Neurotoxicity research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Trial
- 7,8-Dihydroxyflavone improves neuropathological changes in the brain of Tg26 mice, a model for HIV-associated neurocognitive disorder.Scientific reports · 2021Article
- Contribution of CNS cells in NeuroAIDS.Journal of pharmacy & bioallied sciences · 2010Article
- Human immunodeficiency virus-1 evolutionary patterns associated with pathogenic processes in the brain.Journal of neurovirology · 2010Article
- Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China.AIDS (London, England) · 2010Article
- HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications.Journal of leukocyte biology · 2010Review
- A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection.Neuron · 2009Review
- Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis.Glia · 2008Article
- Characterization of peripheral blood human immunodeficiency virus isolates from Hispanic women with cognitive impairment.Journal of neurovirology · 2007Article
- Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2007Review
- Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.Progress in polymer science · 2007Article
- Neurotoxins and neurotoxicity mechanisms. An overview.Neurotoxicity research · 2006Review
- Debate: "is increasing neuroinflammation beneficial for neural repair?".Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2006Review
- HIV-1 associated dementia: symptoms and causes.Retrovirology · 2006Review
- Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases.Neurotoxicity research · 2005Review
- Adjunctive therapies for HIV-1 associated neurologic disease.Neurotoxicity research · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The human immunodeficiency virus-1 (HIV-1) commonly affects cognitive, behavioral and motor functions during the disease course. The neuropathogenesis of viral infection revolves around neurotoxins produced from infected and immune-activated mononuclear phagocytes (MP; perivascular macrophages and microglia). Direct infection of neurons occurs rarely, if at all. Neurologic disease arises in part as a consequence of MP metabolic dysfunction. Although the advent of highly active antiretroviral therapy (HAART) has attenuated the incidence and severity of neurologic disease, it, nonetheless, remains a common and disabling problem for those living with HIV-1 infection. Adjunctive therapies are currently designed to ameliorate clinical outcomes and are included in the therapeutic armamentarium. Anti-inflammatory drugs that inhibit cytokines, chemokines and interferons linked to neurodegenerative processes can significantly ameliorate neuronal function. HIV-1 neurotoxins have the unique ability to up-regulate glycogen synthase kinase-3beta (GSK-3beta) activity that in turn elicits neuronal apoptosis. GSK-3beta inhibitors are neuroprotective in animal models of Neuro AIDS. They are also currently in Phase 1 clinical trials designed for safety and tolerability in patients with HIV-1 infection. Neurotrophins are only beginning to be realized for their therapeutic potential in HIV-1 associated neurologic disease. This review article provides a broad overview of neuroprotective strategies for HIV-1 infection and details how such strategies act and may be implemented for treatment of human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.